Susquehanna International Group
ABVC icon

Susquehanna International Group’s ABVC BioPharma ABVC Stock Holding History

Susquehanna International Group’s Portfolio ABVC Stock Details ABVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,100
Closed -$42.8K – 13070
2025
Q4 		$42.8K Buy
+20,100
New +$53.9K ﹤0.01% 11802

Other funds holding ABVC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Susquehanna International Group's ABVC Position: Q2 2023 in Review

Susquehanna International Group sold out of ABVC BioPharma (ABVC) in Q2 2023, closing a stake of 1,392 shares — an estimated $8.77K sold.

Susquehanna International Group first reported a position in ABVC in Q3 2021 and held it in 4 quarters. The position peaked at $35K in Q3 2021. 9 funds tracked by Wall St. Rank hold ABVC as of Q2 2023.

  • Susquehanna International Group reported no remaining ABVC BioPharma position as of Q2 2023 after selling out during the quarter.
  • Susquehanna International Group sold 1,392 ABVC BioPharma shares in Q2 2023, an estimated $8.77K.
  • Susquehanna International Group first reported a position in ABVC BioPharma in Q3 2021 and held it in 4 quarters.
  • Susquehanna International Group's ABVC BioPharma position peaked at $35K in Q3 2021.
  • 9 funds tracked by Wall St. Rank held ABVC BioPharma as of Q2 2023.

Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.